Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Apr
22
Today In Oncology
Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
Methylation-Based AI Model Classifies Tumors of Unknown Origin
Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo